# Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

> **NCT02719691** · PHASE1 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 47 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Solid Tumors

## Interventions

- **DRUG:** Alisertib
- **DRUG:** MLN0128

## Key facts

- **NCT ID:** NCT02719691
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-13
- **Primary completion:** 2020-03-18
- **Final completion:** 2020-03-18
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719691, "Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02719691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*